The dermal fillers market is about to get even more crowded with the arrival of Elevess, a hyaluronic acid-based injectable filler for facial wrinkles. Although it was approved in July 2007 by the Food and Drug Administration for sale in the United States, Elevess has since remained relatively unknown compared to popular competing hyaluronic acid filler brands such as Restylane and Juvederm. But now, Elevess is poised to gain more popularity with the help of Artes Medical, who has just announced a deal with the makers of Elevess to mass market the filler to American plastic surgery consumers. Artes is the maker of Artefill, a long-lasting wrinkle filler that is popular with individuals seeking semi-permanent fillers.
Manufactured by Anika Therapeutics Inc, Elevess is the first hyaluronic acid-based dermal filler approved by the FDA to incorporate the anesthetic Lidocaine, so the filler may produce fewer side effects such as pain, itching, and tenderness at the point of injection. The prospect of less pain and discomfort should prove to be an attractive benefit to needle-averse patients.
While the pain anesthetic mixture seems to be a novel idea, Elevess is not actually the only hyaluronic acid filler to incorporate an anesthetic in its formula. Earlier this year, Mentor launched Prevelle Silk, which also mixes hyaluronic acid with lidocaine. Prevelle is also FDA approved. Mentor is one of the world’s leading manufacturers of breast implants.
The deal between Artes and Anika will take effect this year, allowing Elevess to be distributed by Artes throughout the United States.none